My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

4.180 -0.050 (-1.18%)
Streaming Delayed Price Updated: 3:54 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 61,581
Open 4.210
Bid (Size) 4.150 (1)
Ask (Size) 4.210 (1)
Prev. Close 4.230
Today's Range 3.950 - 4.230
52wk Range 3.816 - 17.38
Shares Outstanding 41,957,197
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Top movers in Friday's pre-market session
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill

Performance

YTD
-40.5%
-40.5%
1 Month
-5.2%
-5.2%
3 Month
-51.1%
-51.1%
6 Month
-14.8%
-14.8%
1 Year
-72.3%
-72.3%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
What to Expect from Verrica Pharmaceuticals's Earnings
Via Benzinga
Earnings Outlook For Verrica Pharmaceuticals
Via Benzinga
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Posts Profit in Fiscal Q2
Via The Motley Fool
Topics Intellectual Property
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For August 12, 2025
Via Benzinga
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For May 13, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
The current price of Verrica Pharmaceuticals Inc. - Common Stock is 4.180
When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 10/17/25 03:54 PM ET
What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 175.38M
How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
Verrica Pharmaceuticals Inc. - Common Stock has 175M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.